Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has Peter commented on institutional investors lately? With all the latest advancements on contracts and industry relationships, feel this is missing to get the stock price moving.
Thanks for sharing. Where did you pull this? Link isn't working.
Hot take. I don't know if mass marketing would do much for us. Gun violence is a known issue and already talked about by the masses. Conversation usually leads to gun control and the second amendment in the US. Joe Schmo from up the street can't buy PATSCAN even if he is fully aware of Patriot One, security solutions and thinks were are the shit. Targeted sales is what we need. Sales team needs to talk to decision makers, and secure contracts if the solution actually brings value and top tier. Then operations has to execute on install and customer service. Peter references small contracts and pilots with the possibility of large contracts. We need that happen.
So dumb - did they even look at the NASDAQ requirements?
Is this an answer to my question? This video is two years old and their website clear states they have some sort of Evolv or Patriot One Technology.
"New contactless entry technology at Mercedes-Benz Stadium!
Your safety is our primary focus at Mercedes-Benz Stadium. You may notice that we’ve added new security screening technology that permits you to walk through security without removing items from your pockets or having your approved bag physically inspected. This enhanced technology provides us top security while giving you a better experience during the ingress process. As you enter the screening area, keep walking at a normal pace with all of your belongings in your pockets and holding any approved bag. Please do not stop unless advised by Security Personnel."
https://mercedesbenzstadium.com/fan-experience/
Also, I know people who went to the Alabama vs. Miami football game this weekend. Said they didn't have to empty out there pockets but weren't sure if it was Evolv or Patriot One.
https://mercedesbenzstadium.com/fan-experience/
Evolv or Patriot One?
I was at the Tour Championship yesterday, Evolv Technology was being used..
What a crap website. Yeah right that is their annual revenue.
Find details on filings here: https://nhicspac.com/
Thanks for sharing. Interesting valuation. They had less than 5 million in revenue last year.
Patience is a virtue! All we need is an update on testing and I think we soar to new highs.
I'm with you Roland. Long and strong. That was sarcasm for individuals I don't have time doing hw for. I agree, why be here if you aren't holding.
My original post from yesterday was just my opinion of the current state of affairs. Look forward to 2021 and good luck to you.
Lol And to note I have made my fair share on K.M. plays. Glad your looking into me :). I got some other speculative plays we can take offline if you want to hear about them. I trade but mostly are in these for the long haul too. At the end of the day I am still eating steak if I walk away penniless from these penny stocks. I know the risk.
lol a lot of you are losers. Sorry, ALL rhetoric. Just my opinion of trying to pump the stock! Caught! DYOD!!!!
... we as in shareholders or people who actually do research on this stock. Doug, do your own research - TJ Dooley, Reds, Banc of California stadium, Healy School District, Westgate (now Plaza - if you looked into this one carefully you would see it is because the executive from the Westgate moved over to the Plaza).
We have installers, school districts, and casinos buying into testing this technology out and we are hearing great reviews. What do people expect from this last year? Venues, schools, etc. have been shut down? This technology is for large public gatherings which we haven't been able to have. If you think artificial intelligence will continue to grow and there is opportunity in the public security landscape, I don't know how you don't look at this company and see value. DYOD. My opinion. Another biased shareholder who recently picked up more shares.
I think bringing in a new CEO was the right call. Not to downplay Martin's value and what he has done because he has a lot of high level security experience. He probably truly understands where public security lacks from his government roles. COVID-19 didn't help but I think he got into the weeds too much with the possibilities of this technology. Like mobile detection. Those could be great plays but as the new CEO has stated we need to focus on where we can drive revenue NOW. R&D will continue and should as they continue to collect data and have hardware advances. With the COVID-19 aspect added to our platform I just think that facility and venue executives will take a hard look at this technology as we open back up this year. Also, you don't think Xtract's government contracts aren't helping us build out this technology even further? And Bill Magnis, former Johnson Controls Exec, was brought in to make this work similar to how Johnson Controls runs a lot of their business. Do you think they use their own labor to install their manufactured equipment and systems? They do but a lot of it but it is partners too. Regional & local mechanical and electrical firms. That is what Patriot One is still trying to build out as well. They are building partners as they dial in the technology/offering.
Good luck to all and cheers to 2021.
Looks like a patent will be awarded in early January. I believe this will be for the UBC technology not UF/FAIMS. Issue notification mailed on 12/22. Predicted patent issue date is 01/12.
Been a long slow road, but we may be making some moves in 2021.
Information can be found at https://portal.uspto.gov/pair/PublicPair - Application No. 14/689434.
Thanks MS, I don't know if most people here understand who is really shot calling - Kal and Bullrun Capital. Even though the original PR for interim data wasn't worded well, somebody manipulated the stock like a MF. My guess would be Kal or one of his cronies.
lol alright
Maybe it is just me and someone can ease my concern with some insight, but I am still a little hung up on this enrollment rate. I do agree, it was nice to hear Chris let the market know they will be releasing interim data early December. But. Just a couple weeks ago we all expected trial completion and a full data read out by end of year. And I still don't feel like we have gotten a good explanation of why that changed. Why is enrollment not at 100%?
Exactly. We already know you have a trial going on. Bull**** email
My only thought is they may be waiting until trial completion, end of two weeks after final patient? Enrollment should be at 100%. I don't care about unqualified enrollees. Hospitalizations are up. Enrollment shouldn't have slowed.
https://businessjournaldaily.com/covid-19-hospitalizations-spike-to-highest-level-in-ohio/
news is coming just need results
PATSCAN
I must of missed that news release. Why is that? It seems like great technology to add to the platform?
https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00032084&issuerType=03&projectNo=03122878&docId=4813416
Didn't like seeing this. Wonder what happen?
https://www.sotechsecure.com/
Loss on investment in Sotech
As at July 31, 2020, the Company owns a 49% interest in Sotech Secure, LLC ("Sotech"), a Delaware Limited Liability Company with NanoBio Detection Systems LLC ("NanoBio") owning the remaining 51% interest. The Company has experienced challenges with its joint venture partner and has determined that it no longer holds significant influence or joint control over Sotech. Accordingly, the Company has discontinued the use of the equity method during the fourth quarter of 2020.
On September 14, 2020, the Company entered into a membership interest purchase agreement with NanoBio to sell its 49% interest in Sotech for USD $3,000,000 with an estimated closing date of October 31, 2020. Management expects that the proposed transaction will close as planned; however, there is no guarantee that transaction will proceed as expected. The Company has recognized a total loss of $2,549,444 on the investment during the year ended July 31, 2020. This represents a combination of the proportionate share of loss while being accounted for using the equity method of $1,531,817 and a fair value write-down of the investment of $1,017,627 to its fair value of $4,021,200 (USD $3,000,000).
Big dawg! Let's hope it sees value in the marketplace. Got to push it to facilities personnel. Need it to work. Xtract AI is a ticket.
https://www.yardbarker.com/nfl/articles/browns_hoping_to_have_20_percent_capacity_at_home_games_in_2020/s1_13132_32639300
Hoping the PATSCAN technology is a part of their proposal.
https://www.yardbarker.com/mlb/articles/reds_submit_plan_to_allow_fans_to_attend_games/s1_13132_32595566
Getting some interesting coverage in South Miami/from the Hispanic community.
Hospital de Westchester en Miami, invierte en pruebas con Ifenprodil, lo que sería la vacuna en contra del COVID-19. #TVV #TVVNoticias pic.twitter.com/p3GPyX43LH
— TVV Noticias (@TVVnoticias) August 11, 2020
Excited to see what comes of these trials/liking the science behind Ifenprodil. Sorry if this has already been posted. An old Breahtec investor who has stuck around.
https://www.utdallas.edu/news/health-medicine/nerve-cells-lungs-covid-19-2020/
“There’s a striking increase in NMDA (N-methyl-D-aspartate) receptors in immune cells in the lungs that is much different than you see in other diseases,” Price said. “It suggests that maybe the neurons there can communicate with the immune cells via glutamate, the neurotransmitter that NMDA receptors respond to. Interrupting this interaction might lessen the damaging effect.”
http://www.pharmabiz.com/PrintArticle.aspx?aid=129734&sid=2
"NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
The company believes NP-120 can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients."
https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2887841/images.html?page=1&frenchDocType=Poursuite-Amendment&englishDocType=Prosecution-Amendment&modificationDate=20191202&scale=25&rotation=0&type=basic_search&objectName=A1001001A20A06B42856H01469&numPages=12&query=cannabix+technologies&start=&num=
Patent response made public - filed Jan 2nd.
I think it is going to come down to the Yost/FAIMS patent.
US Patent - published 10.10.2019
If you look here Public Patent Application Information Retrieval . Status is Docketed New Case - Ready for Examination. Meaning that the utility patent application has been assigned to an examiner, placed in their docket and that an Office Action will be forthcoming. Newly changed as of 12.03.19. Application Number: 16/082,220. Application Type: Utility
Examiner Name: MACCHIAROLO, PETER J. Group Art Unit:2856
MD&A filed December 9, 2019 (unaudited financial statements and notes thereto for the period ended October 31, 2019). Here is an excerpt about patents:
Oh, so now a patent isn't important? LOL what?! Coke doesn't have a patent because its formula is a closely guarded secret. They don't need it. We do. And yeah it is all good for Rav because he makes out like a bandit either way. Also, I don't even know what that guy does. Must be nice having connections.
Interesting to see M. Huestis name pop back up
https://webfiles.thecse.com/CNSX_Form_11_-_Notice_of_Proposed_Stock_Option_Cannabix_Sep_23_2019.pdf?KE.GGlS8xHSNzZ26UIWMkGBumkU.JF_m
I try to keep my eyes down field and live in the present state of what is happening around me, but I will entertain your 2017 quotes and go back to appease you.
May 2017 Cannabix Quote provided by AMG - "as we prepare for trials with the Cannabix marijuana breathalyzer device".
So to answer your question - I think Cannabix was as far as they thought they were. Obviously they hit some snags in 2017 when they went to do trials with the device. I don't believe for one second N2 had any idea of the inner working of the company/where Cannabix was with the technology. They questioned it, and rightfully so. It has never been done. But I will give you a more recent news release:
July 24, 2019 News Release from Cannabix
"The Company continues to expeditiously conduct trial testing to evaluate the sensitivity and accuracy of the instrument and to collect data to determine variance among test subjects at its Vancouver and Florida development facilities using its FAIMS (field asymmetric waveform ion mobility spectrometry) THC detection device."
So in 2017 we were in preparing for trials and now we are continues to expeditiously conduct trial testing
Cannabix's response to examiners report
http://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2887841/images.html?modificationDate=20190031&page=1&scale=25&rotation=0&englishDocType=Prosecution-Amendment&frenchDocType=Poursuite-Amendment&type=basic_search&objectName=A1001001A19F06A74837H47159&numPages=15&query=cannabix+technologies&start=&num=
Michelle Palumbo (mentioned previously)
https://www.linkedin.com/in/michelleapalumbo6
"Data processing time decreased from eight hours to under three minutes."
Its been a long road. This stock isn't for everyone. Long and speculative
http://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2887841/images.html?modificationDate=20190005&page=1&scale=25&rotation=0&englishDocType=Prosecution-Amendment&frenchDocType=Poursuite-Amendment&type=basic_search&objectName=A1001001A19C05A91039G93199&numPages=5&query=cannabix+technologies&start=1&num=50
Cannabix needs to give a response by June 5th ^^. Hound Labs has started a recent media blitz that isn't doing the stock price any favors. Cannabix isn't providing much information to the market - vidoes of device or interviews. It sounds like internal testing is going well but doesn't seem like they are confident enough yet to really think they got it? Hopefully just waiting for the patent to go through and third-party testing results.
Honestly your old post doesn't prove anything to me, why didn't you include the email with your original post?
Again I am unsure if cannabis is at play or not. I am embracing some debate because I think it could be a possibility. For you guys to say there is no way, 100% positive not at play, is kind of ridiculous.
NASH (where are Chief Science Officer came from) was looking at cannabis and now their first scientific advisor is someone with a cannabis research past? Also, there is a lot of research and thoughts out there that CBD helps liver function/disease.
GLTA
Great post. How about you share that email with us?
How can we not think cannabis may be involved? We aren't talking about the psychoactive molecules of cannabis, cannabis is a complex plant with many different compounds. A lot is unknown regarding the health benefits it may or may not have because of the ban the government has had on the plant.
I don't know if cannabis is involved or not, but look at FACTS in this recent news release. DR ARUN.J SANYAL is involved in cannabis research https://www.sanyalbio.com/
Why would the company ask him? Why we would he accept?
JMO
March 15, 2019 MD&A
"The Company has received office actions and comments from Canadian and US Patent and Trademark Offices since initial filing. As it is entitled to do with all patent applications, the Company is currently preparing to file a response to overcome objections raised in March 2019 to the current claims of the application. The Company filed a Request for Continued Examination of its application with the US Patent Office on June 20, 2018 to distinguish the Company’s technology from prior art patents, and filed a further response on 18 October 2018. There is no assurance that a final patent will be accepted and issued by regulatory authorities."